JY
SLDB icon

Jeff Yass’s Solid Biosciences SLDB Stock Holding History

Jeff Yass’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Sell
163,037
-106,694
-40% -$809K ﹤0.01% 6972
2026
Q1 		$1.94M Sell
269,731
-229,562
-46% -$1.48M ﹤0.01% 6256
2025
Q4 		$2.82M Sell
499,293
-4,373
-0.9% -$23.7K ﹤0.01% 4992
2025
Q3 		$3.11M Buy
503,666
+154,802
+44% +$905K ﹤0.01% 4917
2025
Q2 		$1.7M Buy
348,864
+151,076
+76% +$534K ﹤0.01% 6143
2025
Q1 		$732K Buy
197,788
+144,802
+273% +$620K ﹤0.01% 8036
2024
Q4 		$212K Sell
52,986
-51,571
-49% -$283K ﹤0.01% 10612
2024
Q3 		$729K Buy
104,557
+69,703
+200% +$565K ﹤0.01% 7559
2024
Q2 		$198K Sell
34,854
-182,538
-84% -$1.63M ﹤0.01% 10373
2024
Q1 		$2.9M Buy
217,392
+184,157
+554% +$1.72M ﹤0.01% 4593
2023
Q4 		$204K Buy
+33,235
New +$106K ﹤0.01% 10644
2023
Q2 		– Sell
-18,690
Closed -$88.6K – 13040
2023
Q1 		$88.6K Buy
+18,690
New +$112K ﹤0.01% 11379
2022
Q3 		– Sell
-4,025
Closed -$40.6K – 14040
2022
Q2 		$37K Buy
4,025
+2,736
+212% +$28.4K ﹤0.01% 12134
2022
Q1 		$23K Sell
1,289
-5,465
-81% -$96.4K ﹤0.01% 12585
2021
Q4 		$177K Sell
6,754
-2,701
-29% -$82.5K ﹤0.01% 11590
2021
Q3 		$339K Buy
9,455
+7,834
+483% +$333K ﹤0.01% 10316
2021
Q2 		$89K Sell
1,621
-1,155
-42% -$76.3K ﹤0.01% 12134
2021
Q1 		$230K Buy
2,776
+20
+0.7% +$2.21K ﹤0.01% 11145
2020
Q4 		$313K Buy
2,756
+1,171
+74% +$74.1K ﹤0.01% 9169
2020
Q3 		$48K Sell
1,585
-2,648
-63% -$101K ﹤0.01% 10210
2020
Q2 		$186K Sell
4,233
-16,441
-80% -$683K ﹤0.01% 9102
2020
Q1 		$741K Sell
20,674
-7,425
-26% -$367K ﹤0.01% 6062
2019
Q4 		$1.88M Buy
28,099
+22,020
+362% +$2.43M ﹤0.01% 4435
2019
Q3 		$943K Sell
6,079
-1,154
-16% -$131K ﹤0.01% 5810
2019
Q2 		$624K Sell
7,233
-8,587
-54% -$936K ﹤0.01% 6793
2019
Q1 		$2.18M Buy
+15,820
New +$3.96M ﹤0.01% 3613

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's SLDB Position: Q2 2026 in Review

Jeff Yass reduced its Solid Biosciences (SLDB) stake by 40% in Q2 2026, selling an estimated $809K and leaving 163,037 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #6972.

Jeff Yass first reported a position in SLDB in Q1 2019 and has held it in 26 quarters since. The position peaked at $3.11M in Q3 2025. 155 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Jeff Yass held 163,037 shares of Solid Biosciences worth $1.63M as of Q2 2026.
  • Jeff Yass sold 106,694 Solid Biosciences shares in Q2 2026, an estimated $809K.
  • Solid Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6972 holding.
  • Jeff Yass first reported a position in Solid Biosciences in Q1 2019 and has held it in 26 quarters since.
  • Jeff Yass's Solid Biosciences position peaked at $3.11M in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.